Nature Publishing Group Adds Open Access Options for 7 Journals

The Nature Publishing Group has added open access options for 7 more journals.

Here's an excerpt from the press release:

Nature Publishing Group (NPG) is pleased to announce open access options for seven further journals. Twenty-five journals published by NPG now offer authors an open access option, including all 15 academic journals owned by NPG.

American Journal of Gastroenterology, Bone Marrow Transplantation, Gene Therapy, International Journal of Obesity, Journal of Cerebral Blood Flow and Metabolism, Oncogene, and Leukemia have all recently introduced open access options. Authors publishing in these journals can now choose to make their article open access on payment of an article processing charge (APC). . . .

Including the American Journal of Gastroenterology and Journal of Cerebral Blood Flow and Metabolism, seven journals published by NPG on behalf of societies offer open access options. Other journals in this portfolio with an open access are: British Journal of Cancer, The EMBO Journal, EMBO reports, European Journal of Human Genetics and Molecular Therapy. . . .

Launched in April 2010, Nature Communications is the first Nature-branded online-only journal with an open access option. In 2009, NPG introduced open access options on twelve of its academic journals.

NPG also publishes two fully open access journals: Cell Death and Disease and Molecular Systems Biology. Cell Death & Disease, launched in January 2010, is the open access sister title to Cell Death & Differentiation. Launched in 2005, Molecular Systems Biology is published in association with the European Molecular Biology Organization (EMBO) and has a 2008 Impact Factor of 12.243.

NPG's self-archiving policy ensures that authors of original research papers can comply with funder mandates for public access, regardless of which NPG journal they publish in. In addition, NPG offers a free Manuscript Deposition Service into PubMed Central and UK PubMed Central on 43 of its titles.